No Data
Vcanbio Cell & Gene Engineering Corp., Ltd. (600645.SH): The company has completed the repurchase of 2.58% of its shares at a total cost of 0.2 billion yuan.
On August 1st, Gelunhui reported that Vcanbio Cell & Gene Engineering (600645.SH) announced that on July 31, 2024, the company completed a buyback and had actually repurchased 12,052,740 shares of the company, accounting for 2.58% of the total share capital, with a maximum repurchase price of 21.15 yuan/share, a minimum repurchase price of 15.11 yuan/share, an average repurchase price of 16.59 yuan/share, and a total fund amount of 0.2 billion yuan.
Vcanbio Cell & Gene Engineering Corp., Ltd's (SHSE:600645) Share Price Could Signal Some Risk
vcanbio cell & gene engineering corp.,ltd. (600645.SH) has cumulatively repurchased 2.14% of its shares, costing 168 million yuan.
VCANBIO Cell & Gene Engineering Corp., Ltd. (600645.SH) announced that as of June 30, 2024, the company has repurchased a cumulative total of 10,028,800 shares, accounting for 2.14% of the company's total share capital. The highest purchase price was 21.15 yuan/share and the lowest purchase price was 15.11 yuan/share. The total amount paid was 168 million yuan (excluding transaction fees).
vcanbio cell & gene engineering corp.,ltd. (600645.SH): Cumulative expenditure of 161 million yuan repurchased 2.06% of the shares.
As of June 26, 2024, vcanbio Cell & Gene Engineering Corp., Ltd. (600645.SH) announced that it has repurchased a cumulative total of 9,618,840 shares of the company through centralized bidding trading, accounting for 2.06% of the total share capital of the company. Compared with the last disclosure, it has increased by 0.14%. The highest purchase price was 21.15 yuan/share and the lowest was 15.11 yuan/share. The total amount paid was 161,070,220.30 yuan (excluding transaction commission and other fees).
Is Vcanbio Cell & Gene Engineering (SHSE:600645) Using Too Much Debt?
vcanbio cell & gene engineering corp.,ltd. (600645.SH): Received notice of acceptance for clinical trial application of pharmaceutical VUM02 injection.
On June 20th, Gelunhui reported that its wholly-owned subsidiary, Wuhan Guanggu Zhongyuan Pharmaceutical Co., Ltd., has recently obtained the "Notice of Acceptance" for the clinical trial application of the new indication for VUM02 injection (human umbilical cord-derived mesenchymal stem cell injection) issued by the Drug Evaluation Center (CDE) of the National Medical Products Administration. VUM02 injection, a frozen stem cell preparation independently developed by our company, is a new drug of umbilical cord-derived mesenchymal stem cells (UC-MSC) prepared by screening healthy newborn umbilical cord tissue, separating, amplifying, harvesting, and freezing. Clinical
The Five-year Loss for Vcanbio Cell & Gene Engineering (SHSE:600645) Shareholders Likely Driven by Its Shrinking EarningsNo Data
